近期国内批准抗新型冠状病毒小分子药物研究概况与评价  

Status quo of domestically approved small molecule drugs against novel coronavirus and their application

作　　者：盛吉芳[1] 马亦林[1] Sheng Jifang;Ma Yilin(Department of Infectious Diseases,State Key Laboratory for Diagnosis and Treatment of Infectious Diseases,National Clinical Research Center for Infectious Diseases,the First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China)

机构地区：[1]传染病重症诊治全国重点实验室,国家感染性疾病临床医学研究中心,浙江大学医学院附属第一医院感染病科,杭州310003

出　　处：《中华临床感染病杂志》2023年第5期393-400,共8页Chinese Journal of Clinical Infectious Diseases

摘　　要：2022年以来,国家药品监督管理局批准抗新型冠状病毒(简称新冠病毒)小分子药物上市共有6款,其中2款为进口药物:美国辉瑞公司的Paxlovid(奈玛特韦/利托那韦)与默沙东公司的莫诺拉韦;4款为国产药物:真实生物公司的阿兹夫定、君实生物公司的氢溴酸氘瑞米德韦、先声药业的先诺欣(先诺特韦/利托那韦)及众生药业的来瑞特韦。从整体作用机理上看,这些药物通过作用于新冠病毒蛋白酶及RNA依赖性RNA聚合酶来杀死新冠病毒,如能早期应用,可有效控制临床症状或减少并发症发生。本文对国内新批准的这6种抗病毒小分子药物的研究概况进行阐述,供临床参考。The National Medical Products Administration has approved 6 small molecule drugs against novel coronavirus for marketing since 2022,of which 2 are imported drugs:Paxlovid(Nirmatrelvir/Ritonavir)of Pfizer and Molnupiravir of Merck;4 are domestic products:Azvudine of Real,Deuremidevir Hydrobromide(VV116)of Junshi Biologics,Simnotrelvir/Ritonavir of Simcere pharmaceutical and Leritrelvir of Zhongsheng pharmaceutical.The overall mechanism of action if these drugs is inhibiting protease and RNA-dependent RNA polymerase to eliminate novel coronavirus.If applied early,the clinical symptoms can be effectively controled and complications can be reduced.In this article,the resent progress of 6 newly approved anti-novel coronavirus small molecular drugs in China is reviewed for reference of clinical application.

关 键 词：新型冠状病毒感染 阿兹夫定 氢溴酸氘瑞米德韦 先诺欣 来瑞特韦 抗病毒药物 

分 类 号：R978.7[医药卫生—药品]